Teleflex (NYSE:TFX) Price Target Raised to $130.00

Teleflex (NYSE:TFX) had its price target hoisted by Wells Fargo & Company from $116.00 to $130.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an equal weight rating on the medical technology company’s stock.

Several other research analysts have also recently weighed in on TFX. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $135.00 target price on shares of Teleflex in a report on Wednesday, December 17th. Truist Financial boosted their price target on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a report on Thursday, December 18th. Needham & Company LLC upped their price target on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wall Street Zen cut Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $140.71.

Teleflex Trading Up 2.5%

Teleflex stock opened at $121.95 on Friday. Teleflex has a 52-week low of $100.18 and a 52-week high of $143.32. The company has a market cap of $5.39 billion, a P/E ratio of -5.93, a P/E/G ratio of 3.74 and a beta of 0.87. The company has a quick ratio of 2.01, a current ratio of 2.54 and a debt-to-equity ratio of 0.81. The business has a 50-day simple moving average of $111.34 and a two-hundred day simple moving average of $118.68.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing the consensus estimate of $3.73 by ($1.80). The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $912.57 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.Teleflex’s revenue for the quarter was down 28.5% on a year-over-year basis. During the same quarter last year, the company earned $3.89 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Analysts predict that Teleflex will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. Teleflex’s dividend payout ratio is -6.62%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Empowered Funds LLC grew its holdings in Teleflex by 15.8% during the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after buying an additional 230 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Teleflex by 42.6% during the first quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock worth $877,000 after acquiring an additional 1,895 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Teleflex by 31.5% during the second quarter. Teacher Retirement System of Texas now owns 11,819 shares of the medical technology company’s stock valued at $1,399,000 after acquiring an additional 2,831 shares in the last quarter. Arkadios Wealth Advisors increased its holdings in Teleflex by 61.8% in the 2nd quarter. Arkadios Wealth Advisors now owns 5,403 shares of the medical technology company’s stock valued at $639,000 after acquiring an additional 2,064 shares during the last quarter. Finally, Strs Ohio increased its holdings in Teleflex by 4.9% in the 2nd quarter. Strs Ohio now owns 23,067 shares of the medical technology company’s stock valued at $2,730,000 after acquiring an additional 1,067 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wells Fargo raised its price target to $130 (from $116) and maintained an “equal weight” rating — a near-term bullish signal that can support buying interest. Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $125 (from $115) with a “sector perform” rating — another analyst lift that helps underpin the rally. Read More.
• Positive Sentiment: Teleflex’s board declared a quarterly cash dividend of $0.34 per share (record date March 6, payable March 31), which can attract income-seeking investors and provide support. Read More.
• Positive Sentiment: The company launched a multi‑year restructuring tied to planned divestitures — investors appear to view this as steps to simplify the portfolio, cut costs and potentially unlock value. Read More.
• Neutral Sentiment: Teleflex published its Q4 presentation and full-year results (material and earnings‑call transcripts are available) — useful for modeling but not a driver by itself. Read More.
• Negative Sentiment: Q4 results missed materially: EPS $1.93 vs. consensus ~$3.73 and revenue $569M vs. ~$912.6M — revenue fell ~28.5% year-over-year and margins contracted, a clear near-term negative for earnings momentum. Read More.
• Negative Sentiment: FY‑2026 guidance was significantly reduced: EPS guidance of $6.25–$6.55 and revenue guidance around $2.3B vs. street expectations materially higher (~$15 EPS and ~$3.7B revenue), which is a major downward re‑rating of near-term expectations. Read More.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.